Help

BI’s Article search uses Boolean search capabilities. If you are not familiar with these principles, here are some quick tips.

To search specifically for more than one word, put the search term in quotation marks. For example, “workers compensation”. This will limit your search to that combination of words.

To search for a combination of terms, use quotations and the & symbol. For example, “hurricane” & “loss”.

Login Register Subscribe

Workers comp drug spending down 8.7% nationwide

Reprints
Workers comp drug spending down 8.7% nationwide

More control over drugs such as powerful opioids, better integration with pharmacy benefits managers and prescriber interventions are among the reasons employers spent 8.7 % less in workers compensation drugs costs in 2015, according to a survey released Tuesday by a workers compensation PBM consortium.

CompPharma L.L.C.’s 13th annual Survey of Prescription Drug Management in Workers’ Compensation study revealed the latest round of data to be in line with a steady decrease in spending, with payers surveyed since 2011 having seen costs drop by 11%. The downward trend was interrupted in 2014 with a 6.4% increase over 2013’s results, an increase CompPharma pinned on inflation. 

The current decrease, meanwhile, was not related to a lower number of claims, the report states.

“Twenty percent of the respondents also had assertive settlement initiatives and have been closing older claims,” Joseph Paduda, president of CompPharma, said in a statement. “Overall, payers have seen drug costs go down by 11% in the past six years despite the 2014 increase.”

According to the survey, opioids remained the No. 1 payer concern. The report states that workers comp payers spent $1.54 billion on opioids in 2015, which was 13% of the total spent on opioids in the United States. The report compared this to the total work comp medical spend of less than 1.25% nationwide.

All payers surveyed have opioid management programs to limit the number of opioid prescriptions, according to the statement.

Meanwhile, reactions to PBM consolidations were mixed: Some respondents hoped mergers would bring better pricing and more clinical capabilities, while others expressed concern that the lack of competition would breed complacency.

“There is a sense of acceptance along with a little wariness about potential customer service issues,” Mr. Paduda said. “Consolidation in other segments of the industry has spawned customer service problems when people-based operating models were replaced with offshored or tech-enabled models.”

Researchers analyzed 2015 pharmacy cost data of 30 workers compensation insurance carriers, third-party administrators, self-insured employers and state funds.

 

 

 

 

Read Next